Subscribe

Glossary

Autoantibody

An antibody your immune system has made against part of your own body. It's a finding rather than a diagnosis, and a large share of healthy people have one.

An autoantibody is an antibody aimed at you. About one in seven adults has one of the most common ones, on testing at a standard dilution. Almost all of them never develop a disease.

Quick answerAn autoantibody is an antibody aimed at part of your own body rather than at an infection, and having one is a finding rather than a diagnosis. One survey covered 4,754 Americans and found antinuclear antibodies in 13.8 percent of them. That works out at more than 32 million people.
The follow-up data is what settles this. One study screened 825 healthy blood donors, of whom 130 tested positive on at least one test, and followed them for five years, and in that time only two got a systemic autoimmune rheumatic diagnosis. So a positive result in somebody with no symptoms is usually just a positive result. What changes the meaning is the picture around it, because one antibody means one thing in a person with swollen joints and quite another in a person who feels well.

What the word means

An antibody is something your immune system makes to pick out what doesn't belong, and a virus or a bacterium is the usual target. An autoantibody is one that has picked out part of you instead, so the prefix does all the work here. The finding it describes is a piece of information about your immune system rather than a diagnosis.

That difference is the whole subject of this page, and almost every misunderstanding about these tests comes from losing it. A result reporting an autoantibody says something is being recognized that shouldn't be. It doesn't say anything is being damaged, it doesn't say a disease is present, and it doesn't say one is coming.

The most common of these tests is the antinuclear antibody, shortened to ANA, which looks for antibodies against parts of the cell nucleus. Every prevalence figure on this page describes that one test, because that's where the population data is. The general lesson applies more widely than the figures do.

Why the strength of the result changes what it means

A positive antinuclear antibody isn't one thing. The test is done at a dilution, the result depends heavily on which dilution was used, and two people described as positive may be in quite different situations. The healthy population data makes that plain.

In apparently healthy people it was 31.7 percent at a 1 to 40 dilution, 13.3 percent at 1 to 80, 5.0 percent at 1 to 160, and 3.3 percent at 1 to 320. So nearly a third of healthy people are positive at the weakest dilution while about one in thirty are at the strongest. That study looked across four age groups from 20 to 60, and the rate didn't differ much between them.

The practical result is a question worth asking, which is at what dilution your own result was positive. A weak positive at a low dilution is common. A strong positive is much less common, and that's what gives it more weight in a clinical picture that fits it.

Common misconceptions.

Myth. Having an autoantibody means I have an autoimmune disease.

Reality. It doesn't, and the numbers aren't close. One US survey found antinuclear antibodies in 13.8 percent of people, which works out at more than 32 million, and the great majority of them have no autoimmune disease. Another study screened 825 healthy blood donors, of whom 130 tested positive, and only two got a systemic autoimmune rheumatic diagnosis over five years.

Myth. A positive result means I'll develop something eventually.

Reality. The only follow-up study in our sources says otherwise. It had 130 healthy blood donors who tested positive, and two had a diagnosis after five years. That's a small study followed for a short time, so it can't rule out later disease in anybody, and it argues strongly against one particular reading. A positive result isn't a countdown, and living as though you're already ill is its own harm.

Myth. The strength of the result doesn't change what it means.

Reality. It changes it a great deal, which is why the dilution counts. In apparently healthy people, results fell as the dilution rose, from 31.7 percent at 1 to 40 down to 3.3 percent at 1 to 320. So a weak positive at a low dilution is common in people with nothing wrong, while a strong positive is much less so. Asking at what dilution your result was positive is a fair question.

Myth. If a test is named after a disease, it's a test for that disease.

Reality. Rheumatoid factor is the clearest case of that going wrong. It cleared 85 percent of the people who didn't have rheumatoid arthritis, so roughly 15 percent of them test positive anyway, and it caught only 69 percent of the cases, so about three in ten people with the disease test negative. The name records where the antibody was first found rather than what a result proves.

Related terms.

  • ANA, the most common autoantibody test and the one all the prevalence figures here describe.
  • Rheumatoid factor, the clearest example of a test whose name oversells it.
  • Anti-CCP, which carries more diagnostic weight without finding more cases.
  • Lupus and blood tests, where the antinuclear antibody does its most useful work.

References.

  1. Satoh M; Chan E; Ho L et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis & Rheumatism. 2012;64:2319-2327. 10.1002/art.34380Cross-sectional analysis of a nationally representative population survey
  2. Andraos R; Ahmad A; Wirestam L et al. Screening for autoimmune diseases in apparently healthy antinuclear antibody positive individuals. Frontiers in Medicine. 2024;11. 10.3389/fmed.2024.1455673Prospective screening study of 825 consecutive apparently healthy blood donors with structured questionnaire
  3. Tan EM; Feltkamp TE; Smolen JS et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis and rheumatism. 1997;40:1601-11. 10.1002/art.1780400909Multicentre cross-sectional study of a putatively normal population across 15 international laboratories
  4. Fitch-Rogalsky C; Steber W; Mahler M et al. Clinical and Serological Features of Patients Referred through a Rheumatology Triage System because of Positive Antinuclear Antibodies. PLoS ONE. 2014;9:e93812. 10.1371/journal.pone.0093812Cross-sectional retrospective analysis of a central rheumatology triage database
  5. Nishimura K; Sugiyama D; Kogata Y et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Annals of internal medicine. 2007;146:797-808. 10.7326/0003-4819-146-11-200706050-00008Diagnostic accuracy meta-analysis

Free download

The First Changes to Make.

The same handout I hand my own patients: the specific food and daily-exposure changes worth making first, no guesswork required.

We'll email you the list and keep your address so we can send you something occasionally. We won't sell it or pass it on, and you can unsubscribe from any email. How we handle it.

No spam · Unsubscribe any time

This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.